BEONTAG
17.1.2023 12:01:56 CET | Business Wire | Press release
Today, Beontag – one of the world’s largest manufacturers of self-adhesives and smart tags (such as digital labels, and labeling technology solutions like RFID and NFC) – announced that Tags Lux Sarl., a wholly owned subsidiary of the Company, has secured and closed a binding agreement for a syndicated loan of €120 million with global banks and Deutsche Bank as sole lead arranger.
Beontag, the second largest provider of digital RFID and NFC solutions for some of the world’s biggest fashion and consumer brands, is expected to achieve €550 Million in revenue for 2022, with international and national acquisitions, integrations and expansion contributing to significant top-line growth from pro forma actualized revenues of more than €400 Million in 2021. This is the first significant, international capital raise by the Brazilian-founded company – with operations now spanning more than 15 international facilities and a presence in over 40 countries.
Terms of Syndicated Facility
- The syndicated loan shall mature within 60 months from closing date with 18 months grace period, including a possibility of prepayment from the 18th month.
- Beontag intends to use the net proceeds from the issuance to primarily refinance its existing debt throughout the group. Any excess proceeds will be used to support organic strategic initiatives across multiple geographies and enhance liquidity.
- The transaction is expected to be leverage-neutral after closing.
- The loan shall carry an interest rate of EURIBOR plus 4.5% per annum and contains incentivised terms that are linked to Beontag 2030 ESG strategy, which is aligned to the United Nations Sustainable Development Goals (SDGs). Every year, Beontag will seek third-party verification to certify and report upon progress against the ESG-related terms agreed.
Global Expansion, Borderless Solutions
Beontag’s Chief Financial Officer, Pedro Christ, commented: “Investment is a key aspect of our journey to become a truly borderless, end-to-end solutions provider of self-adhesive label stock and IoT solutions. And we believe this syndicated capital raise is a good example of the confidence of international investors in Beontag’s global strategy, as well as our current operational fundamentals.
For 2023, and beyond, we are excited to continue to innovate and expand our solutions to meet our clients’ demands for future-focused support, all while taking care to improve our ESG credentials and reduce the impact of our sector on the planet.”
The Managing Director of Global Emerging Markets from Deutsche Bank, Ricardo Cunha, added: “We are delighted to partner with Beontag for this transaction. This commitment, with and added ESG incentive, reflects our confidence in both the strength and sustainable intention of their innovative plans for the sector.
We look forward to keep supporting Beontag as the company expands into different markets and geographies.”
ENDS
ABOUT BEONTAG
For more than 40 years, Beontag has been dedicated to developing the future of pressure sensitive label stock and RFID technology, being world leaders in both segments. Today the company’s dedicated team, leading technology, global reach, and capabilities help the world work more efficiently, reliably, and safely. Beontag´s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill Beontag´s mission to be a digital enabler.
With modern manufacturing facilities, permanent investment and a highly qualified team, the company has been expanding its business globally and is one of the largest and most respected self-adhesive companies in Latin America. It also operates in the technology sector and has a wide portfolio of Internet of Things (IoT) solutions, focused on the manufacture of radiofrequency smart labels, as well as on the development of software for the integration of the logistics chain, traceability, and product authentication.
To learn more, visit: https://beontag.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
